title: Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.
abstract: OBJECTIVE
  One of the major hurdles facing nanomedicines is the antibody production against nanoparticles that subsequently results in their opsonization and clearance by macrophages. The objective of this research was to examine and identify the sequence of a low-immunogenic peptide based on recombinant elastin-like polypeptides (ELPs) that does not evoke IgG response and can potentially be used for masking the surfaces of the nanoparticles.
  
  
  METHODS
  Biopolymers composed of a DNA condensing domain in fusion with anionic, neutral and cationic elastin-like peptides were genetically engineered. The biopolymers were used to complex with plasmid DNA and form ELP-coated nanoparticles. Then, the potential immunogenicity of nanoparticles in terms of IgM/IgG response after repeated injections was evaluated in Balb/c immunocompetent mice.
  
  
  RESULTS
  The results revealed the sequence of a non-immunogenic ELP construct that in comparison to control group did not elicit any significant IgG response, whereas the vector/DNA complexes that were coated with polyethylene glycol (PEG) did elicit significant IgG response under the same conditions.
  
  
  CONCLUSIONS
  The identification of the sequence of an ELP-based peptide that does not induce IgG response opens the door to more focused in-depth immunotoxicological studies which could ultimately lead to the production of safer and more effective drug/gene delivery systems such as liposomes, micelles, polymeric nanoparticles, viruses and antibodies.
authors.affiliation: Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 08854, USA.
authors.forename: Faranak S
authors.initials: FS
authors.lastname: Nouri
authors.forename: Xing
authors.initials: X
authors.lastname: Wang
authors.forename: Xuguang
authors.initials: X
authors.lastname: Chen
authors.forename: Arash
authors.initials: A
authors.lastname: Hatefi
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D004247:DNA / Q000737:chemistry* / Q000276:immunology; D004549:Elastin / Q000737:chemistry* / Q000276:immunology; D005822:Genetic Vectors / Q000737:chemistry* / Q000276:immunology; D007107:Immune System / Q000187:drug effects*; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry* / Q000276:immunology
chemical_list: D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010455:Peptides; D004247:DNA; D004549:Elastin
references.citation: Expert Opin Drug Deliv. 2004 Nov;1(1):115-25
references.pmid: 16296724
references.citation: Biomacromolecules. 2002 Sep-Oct;3(5):910-6
references.pmid: 12217035
references.citation: J Control Release. 2011 Dec 20;156(3):374-80
references.pmid: 21864599
references.citation: Mol Ther. 2006 Feb;13(2):328-37
references.pmid: 16275098
references.citation: Expert Rev Vaccines. 2007 Oct;6(5):785-96
references.pmid: 17931158
references.citation: Pathol Biol (Paris). 1985 Apr;33(4):266-74
references.pmid: 3892457
references.citation: J Control Release. 2009 Sep 15;138(3):188-96
references.pmid: 19379785
references.citation: J Control Release. 2006 May 1;112(1):15-25
references.pmid: 16515818
references.citation: Biomacromolecules. 2005 Jan-Feb;6(1):318-23
references.pmid: 15638535
references.citation: Biosci Rep. 2002 Apr;22(2):197-224
references.pmid: 12428901
references.citation: Protein Sci. 2012 Jun;21(6):743-50
references.pmid: 22434766
references.citation: Expert Opin Drug Discov. 2010 Nov;5(11):1067-79
references.pmid: 22827745
references.citation: Eur J Pharm Biopharm. 2012 Jun;81(2):294-302
references.pmid: 22487055
references.citation: J Bacteriol. 1973 Jun;114(3):1143-50
references.pmid: 4576399
references.citation: Gene Ther Mol Biol. 2009;13(A):15-19
references.pmid: 19503758
references.citation: Adv Drug Deliv Rev. 2010 Dec 30;62(15):1404-55
references.pmid: 20655344
references.citation: J Am Chem Soc. 2004 Apr 7;126(13):4199-210
references.pmid: 15053609
references.citation: Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313
references.pmid: 10915952
references.citation: J Am Chem Soc. 2004 Oct 20;126(41):13212-3
references.pmid: 15479061
references.citation: Int J Pharm. 2010 Nov 30;401(1-2):87-92
references.pmid: 20837122
references.citation: Biopolymers. 1992 Sep;32(9):1243-50
references.pmid: 1420991
references.citation: Drug Deliv Transl Res. 2013 Dec;3(6):499-503
references.pmid: 24932437
references.citation: DNA Cell Biol. 1999 Sep;18(9):663-70
references.pmid: 10492397
references.citation: Small. 2013 Aug 26;9(16):2774-83
references.pmid: 23468416
references.citation: J Control Release. 2011 Apr 10;151(1):95-101
references.pmid: 21192992
references.citation: Nanoscale. 2011 May;3(5):2307-14
references.pmid: 21499635
references.citation: Biomaterials. 2003 Oct;24(23):4245-52
references.pmid: 12853256
references.citation: J Control Release. 2006 Oct 10;115(2):175-82
references.pmid: 16959360
references.citation: Nat Biotechnol. 2008 May;26(5):549-51
references.pmid: 18438402
references.citation: J Control Release. 2005 Feb 16;102(3):711-24
references.pmid: 15681092
references.citation: Lab Anim (NY). 2011 May;40(5):155-60
references.pmid: 21508954
references.citation: Drug Deliv. 2005 Jan-Feb;12(1):1-6
references.pmid: 15801714
references.citation: Prog Lipid Res. 2003 Nov;42(6):463-78
references.pmid: 14559067
references.citation: Mol Ther. 2004 Feb;9(2):249-61
references.pmid: 14759809
references.citation: Nanomedicine. 2012 Aug;8(6):833-41
references.pmid: 22033082
references.citation: Biochim Biophys Acta. 2001 Jul 2;1513(1):25-37
references.pmid: 11427191